Ixazomib
Ixazomib market is segmented by region (country), players, by Type and by Application. Players, s ... Read More
Global and United States Immunotherapy Drugs for Multiple Myeloma Market Report & Forecast 2023-2028
1 Study Coverage
1.1 Immunotherapy Drugs for Multiple Myeloma Revenue in Immunotherapy Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million) Introduction
1.2 Global Immunotherapy Drugs for Multiple Myeloma Outlook 2017 VS 2022 VS 2028
1.2.1 Global Immunotherapy Drugs for Multiple Myeloma Market Size for the Year 2017-2028
1.2.2 Global Immunotherapy Drugs for Multiple Myeloma Market Size for the Year 2017-2028
1.3 Immunotherapy Drugs for Multiple Myeloma Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.3.1 The Market Share of United States Immunotherapy Drugs for Multiple Myeloma in Global, 2017 VS 2022 VS 2028
1.3.2 The Growth Rate of Immunotherapy Drugs for Multiple Myeloma Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4 Immunotherapy Drugs for Multiple Myeloma Market Dynamics
1.4.1 Immunotherapy Drugs for Multiple Myeloma Industry Trends
1.4.2 Immunotherapy Drugs for Multiple Myeloma Market Drivers
1.4.3 Immunotherapy Drugs for Multiple Myeloma Market Challenges
1.4.4 Immunotherapy Drugs for Multiple Myeloma Market Restraints
1.5 Study Objectives
1.6 Years Considered
2 Immunotherapy Drugs for Multiple Myeloma by Type
2.1 Immunotherapy Drugs for Multiple Myeloma Market Segment by Type
2.1.1 INF-α
2.1.2 IL-6
2.1.3 Rituximab
2.1.4 Other
2.2 Global Immunotherapy Drugs for Multiple Myeloma Market Size by Type (2017, 2022 & 2028)
2.3 Global Immunotherapy Drugs for Multiple Myeloma Market Size by Type (2017-2028)
2.4 United States Immunotherapy Drugs for Multiple Myeloma Market Size by Type (2017, 2022 & 2028)
2.5 United States Immunotherapy Drugs for Multiple Myeloma Market Size by Type (2017-2028)
3 Immunotherapy Drugs for Multiple Myeloma by Application
3.1 Immunotherapy Drugs for Multiple Myeloma Market Segment by Application
3.1.1 Hospital
3.1.2 Drug Center
3.1.3 Clinic
3.1.4 Other
3.2 Global Immunotherapy Drugs for Multiple Myeloma Market Size by Application (2017, 2022 & 2028)
3.3 Global Immunotherapy Drugs for Multiple Myeloma Market Size by Application (2017-2028)
3.4 United States Immunotherapy Drugs for Multiple Myeloma Market Size by Application (2017, 2022 & 2028)
3.5 United States Immunotherapy Drugs for Multiple Myeloma Market Size by Application (2017-2028)
4 Global Immunotherapy Drugs for Multiple Myeloma Competitor Landscape by Company
4.1 Global Immunotherapy Drugs for Multiple Myeloma Market Size by Company
4.1.1 Top Global Immunotherapy Drugs for Multiple Myeloma Companies Ranked by Revenue (2021)
4.1.2 Global Immunotherapy Drugs for Multiple Myeloma Revenue by Player (2017-2022)
4.2 Global Immunotherapy Drugs for Multiple Myeloma Concentration Ratio (CR)
4.2.1 Immunotherapy Drugs for Multiple Myeloma Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Companies of Immunotherapy Drugs for Multiple Myeloma in 2021
4.2.3 Global Immunotherapy Drugs for Multiple Myeloma Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Immunotherapy Drugs for Multiple Myeloma Headquarters, Revenue in Immunotherapy Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million) Type
4.3.1 Global Immunotherapy Drugs for Multiple Myeloma Headquarters and Area Served
4.3.2 Global Immunotherapy Drugs for Multiple Myeloma Companies Revenue in Immunotherapy Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million) Type
4.3.3 Date of International Companies Enter into Immunotherapy Drugs for Multiple Myeloma Market
4.4 Companies Mergers & Acquisitions, Expansion Plans
4.5 United States Immunotherapy Drugs for Multiple Myeloma Market Size by Company
4.5.1 Top Immunotherapy Drugs for Multiple Myeloma Players in United States, Ranked by Revenue (2021)
4.5.2 United States Immunotherapy Drugs for Multiple Myeloma Revenue by Players (2020, 2021 & 2022)
5 Global Immunotherapy Drugs for Multiple Myeloma Market Size by Region
5.1 Global Immunotherapy Drugs for Multiple Myeloma Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Immunotherapy Drugs for Multiple Myeloma Market Size by Region (2017-2028)
5.2.1 Global Immunotherapy Drugs for Multiple Myeloma Market Size by Region: 2017-2022
5.2.2 Global Immunotherapy Drugs for Multiple Myeloma Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Immunotherapy Drugs for Multiple Myeloma Market Size YoY Growth 2017-2028
6.1.2 North America Immunotherapy Drugs for Multiple Myeloma Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Immunotherapy Drugs for Multiple Myeloma Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Immunotherapy Drugs for Multiple Myeloma Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Immunotherapy Drugs for Multiple Myeloma Market Size YoY Growth 2017-2028
6.3.2 Europe Immunotherapy Drugs for Multiple Myeloma Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Immunotherapy Drugs for Multiple Myeloma Market Size YoY Growth 2017-2028
6.4.2 Latin America Immunotherapy Drugs for Multiple Myeloma Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Immunotherapy Drugs for Multiple Myeloma Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Immunotherapy Drugs for Multiple Myeloma Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Tonghua Dongbao Pharmaceutical
7.1.1 Tonghua Dongbao Pharmaceutical Company Details
7.1.2 Tonghua Dongbao Pharmaceutical Business Overview
7.1.3 Tonghua Dongbao Pharmaceutical Immunotherapy Drugs for Multiple Myeloma Introduction
7.1.4 Tonghua Dongbao Pharmaceutical Revenue in Immunotherapy Drugs for Multiple Myeloma Business (2017-2022)
7.1.5 Tonghua Dongbao Pharmaceutical Recent Development
7.2 Sumitomo
7.2.1 Sumitomo Company Details
7.2.2 Sumitomo Business Overview
7.2.3 Sumitomo Immunotherapy Drugs for Multiple Myeloma Introduction
7.2.4 Sumitomo Revenue in Immunotherapy Drugs for Multiple Myeloma Business (2017-2022)
7.2.5 Sumitomo Recent Development
7.3 Merck
7.3.1 Merck Company Details
7.3.2 Merck Business Overview
7.3.3 Merck Immunotherapy Drugs for Multiple Myeloma Introduction
7.3.4 Merck Revenue in Immunotherapy Drugs for Multiple Myeloma Business (2017-2022)
7.3.5 Merck Recent Development
7.4 Biogen
7.4.1 Biogen Company Details
7.4.2 Biogen Business Overview
7.4.3 Biogen Immunotherapy Drugs for Multiple Myeloma Introduction
7.4.4 Biogen Revenue in Immunotherapy Drugs for Multiple Myeloma Business (2017-2022)
7.4.5 Biogen Recent Development
7.5 Schering-Plough
7.5.1 Schering-Plough Company Details
7.5.2 Schering-Plough Business Overview
7.5.3 Schering-Plough Immunotherapy Drugs for Multiple Myeloma Introduction
7.5.4 Schering-Plough Revenue in Immunotherapy Drugs for Multiple Myeloma Business (2017-2022)
7.5.5 Schering-Plough Recent Development
7.6 Roche
7.6.1 Roche Company Details
7.6.2 Roche Business Overview
7.6.3 Roche Immunotherapy Drugs for Multiple Myeloma Introduction
7.6.4 Roche Revenue in Immunotherapy Drugs for Multiple Myeloma Business (2017-2022)
7.6.5 Roche Recent Development
7.7 Glaxo
7.7.1 Glaxo Company Details
7.7.2 Glaxo Business Overview
7.7.3 Glaxo Immunotherapy Drugs for Multiple Myeloma Introduction
7.7.4 Glaxo Revenue in Immunotherapy Drugs for Multiple Myeloma Business (2017-2022)
7.7.5 Glaxo Recent Development
7.8 Chiron
7.8.1 Chiron Company Details
7.8.2 Chiron Business Overview
7.8.3 Chiron Immunotherapy Drugs for Multiple Myeloma Introduction
7.8.4 Chiron Revenue in Immunotherapy Drugs for Multiple Myeloma Business (2017-2022)
7.8.5 Chiron Recent Development
8 Research Findings and Conclusion
9 Appendix
9.1 Research Methodology
9.1.1 Methodology/Research Approach
9.1.2 Data Source
9.2 Author Details
9.3 Disclaimer
List of Tables
Table 1. Immunotherapy Drugs for Multiple Myeloma Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028)
Table 2. Immunotherapy Drugs for Multiple Myeloma Market Trends
Table 3. Immunotherapy Drugs for Multiple Myeloma Market Drivers
Table 4. Immunotherapy Drugs for Multiple Myeloma Market Challenges
Table 5. Immunotherapy Drugs for Multiple Myeloma Market Restraints
Table 6. Global Immunotherapy Drugs for Multiple Myeloma Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 7. United States Immunotherapy Drugs for Multiple Myeloma Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 8. Global Immunotherapy Drugs for Multiple Myeloma Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 9. United States Immunotherapy Drugs for Multiple Myeloma Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 10. Top Immunotherapy Drugs for Multiple Myeloma Companies in Global Market, Ranking by Revenue (2021)
Table 11. Global Immunotherapy Drugs for Multiple Myeloma Revenue by Player, (US$ Million), 2017-2022
Table 12. Global Immunotherapy Drugs for Multiple Myeloma Revenue Share by Player, 2017-2022
Table 13. Global Immunotherapy Drugs for Multiple Myeloma Companies Market Concentration Ratio (CR5 and HHI)
Table 14. Global Immunotherapy Drugs for Multiple Myeloma by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immunotherapy Drugs for Multiple Myeloma as of 2021)
Table 15. Top Players of Immunotherapy Drugs for Multiple Myeloma in Global Market, Headquarters and Area Served
Table 16. Companies Revenue in Immunotherapy Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million) Type
Table 17. Date of International Companies Enter into Immunotherapy Drugs for Multiple Myeloma Market
Table 18. Companies Mergers & Acquisitions, Expansion Plans
Table 19. Top Immunotherapy Drugs for Multiple Myeloma Players in United States Market, Ranking by Revenue (2021)
Table 20. United States Immunotherapy Drugs for Multiple Myeloma Revenue by Players, (US$ Million), 2020, 2021 & 2022
Table 21. United States Immunotherapy Drugs for Multiple Myeloma Revenue Share by Players, 2020, 2021 & 2022
Table 22. Global Immunotherapy Drugs for Multiple Myeloma Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
Table 23. Global Immunotherapy Drugs for Multiple Myeloma Market Size by Region (2017-2022) & (US$ Million)
Table 24. Global Immunotherapy Drugs for Multiple Myeloma Market Size Forecast by Region (2023-2028) & (US$ Million)
Table 25. North America Immunotherapy Drugs for Multiple Myeloma Sales in Value by Country (2017-2028) & (US$ Million)
Table 26. Asia Pacific Immunotherapy Drugs for Multiple Myeloma Sales in Value by Region (2017-2028) & (US$ Million)
Table 27. Europe Immunotherapy Drugs for Multiple Myeloma Sales in Value by Country (2017-2028) & (US$ Million)
Table 28. Latin Americaa Immunotherapy Drugs for Multiple Myeloma Sales in Value by Country (2017-2028) & (US$ Million)
Table 29. Middle East and Africa Immunotherapy Drugs for Multiple Myeloma Sales in Value by Country (2017-2028) & (US$ Million)
Table 30. Tonghua Dongbao Pharmaceutical Company Details
Table 31. Tonghua Dongbao Pharmaceutical Business Overview
Table 32. Tonghua Dongbao Pharmaceutical Immunotherapy Drugs for Multiple Myeloma Product
Table 33. Tonghua Dongbao Pharmaceutical Revenue in Immunotherapy Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
Table 34. Tonghua Dongbao Pharmaceutical Recent Development
Table 35. Sumitomo Company Details
Table 36. Sumitomo Business Overview
Table 37. Sumitomo Immunotherapy Drugs for Multiple Myeloma Product
Table 38. Sumitomo Revenue in Immunotherapy Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
Table 39. Sumitomo Recent Development
Table 40. Merck Company Details
Table 41. Merck Business Overview
Table 42. Merck Immunotherapy Drugs for Multiple Myeloma Product
Table 43. Merck Revenue in Immunotherapy Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
Table 44. Merck Recent Development
Table 45. Biogen Company Details
Table 46. Biogen Business Overview
Table 47. Biogen Immunotherapy Drugs for Multiple Myeloma Product
Table 48. Biogen Revenue in Immunotherapy Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
Table 49. Biogen Recent Development
Table 50. Schering-Plough Company Details
Table 51. Schering-Plough Business Overview
Table 52. Schering-Plough Immunotherapy Drugs for Multiple Myeloma Product
Table 53. Schering-Plough Revenue in Immunotherapy Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
Table 54. Schering-Plough Recent Development
Table 55. Roche Company Details
Table 56. Roche Business Overview
Table 57. Roche Immunotherapy Drugs for Multiple Myeloma Product
Table 58. Roche Revenue in Immunotherapy Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
Table 59. Roche Recent Development
Table 60. Glaxo Company Details
Table 61. Glaxo Business Overview
Table 62. Glaxo Immunotherapy Drugs for Multiple Myeloma Product
Table 63. Glaxo Revenue in Immunotherapy Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
Table 64. Glaxo Recent Development
Table 65. Chiron Company Details
Table 66. Chiron Business Overview
Table 67. Chiron Immunotherapy Drugs for Multiple Myeloma Product
Table 68. Chiron Revenue in Immunotherapy Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
Table 69. Chiron Recent Development
Table 70. Research Programs/Design for This Report
Table 71. Key Data Information from Secondary Sources
Table 72. Key Data Information from Primary Sources
List of Figures
Figure 1. Immunotherapy Drugs for Multiple Myeloma Product Picture
Figure 2. Global Immunotherapy Drugs for Multiple Myeloma Market Size, (US$ Million), 2017 VS 2022 VS 2028
Figure 3. Global Immunotherapy Drugs for Multiple Myeloma Market Size 2017-2028 (US$ Million)
Figure 4. United States Immunotherapy Drugs for Multiple Myeloma Market Size, (US$ Million), 2017 VS 2022 VS 2028
Figure 5. United States Immunotherapy Drugs for Multiple Myeloma Market Size 2017-2028 (US$ Million)
Figure 6. United States Immunotherapy Drugs for Multiple Myeloma Market Share in Global 2017-2028
Figure 7. Immunotherapy Drugs for Multiple Myeloma Report Years Considered
Figure 8. Product Picture of INF-α
Figure 9. Product Picture of IL-6
Figure 10. Product Picture of Rituximab
Figure 11. Product Picture of Other
Figure 12. Global Immunotherapy Drugs for Multiple Myeloma Market Share by Type in 2022 & 2028
Figure 13. Global Immunotherapy Drugs for Multiple Myeloma Market Size by Type (2017-2028) & (US$ Million)
Figure 14. Global Immunotherapy Drugs for Multiple Myeloma Market Share by Type (2017-2028)
Figure 15. United States Immunotherapy Drugs for Multiple Myeloma Market Share by Type in 2022 & 2028
Figure 16. United States Immunotherapy Drugs for Multiple Myeloma Market Size by Type (2017-2028) & (US$ Million)
Figure 17. United States Immunotherapy Drugs for Multiple Myeloma Market Share by Type (2017-2028)
Figure 18. Product Picture of Hospital
Figure 19. Product Picture of Drug Center
Figure 20. Product Picture of Clinic
Figure 21. Product Picture of Other
Figure 22. Global Immunotherapy Drugs for Multiple Myeloma Market Share by Application in 2022 & 2028
Figure 23. Global Immunotherapy Drugs for Multiple Myeloma Market Size by Application (2017-2028) & (US$ Million)
Figure 24. Global Immunotherapy Drugs for Multiple Myeloma Market Share by Application (2017-2028)
Figure 25. United States Immunotherapy Drugs for Multiple Myeloma Market Share by Application in 2022 & 2028
Figure 26. United States Immunotherapy Drugs for Multiple Myeloma Market Size by Application (2017-2028) & (US$ Million)
Figure 27. United States Immunotherapy Drugs for Multiple Myeloma Market Share by Application (2017-2028)
Figure 28. North America Immunotherapy Drugs for Multiple Myeloma Market Size Growth Rate 2017-2028 (US$ Million)
Figure 29. U.S. Immunotherapy Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 30. Canada Immunotherapy Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 31. Europe Immunotherapy Drugs for Multiple Myeloma Market Size Growth Rate 2017-2028 (US$ Million)
Figure 32. Germany Immunotherapy Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 33. France Immunotherapy Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 34. U.K. Immunotherapy Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 35. Italy Immunotherapy Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 36. Russia Immunotherapy Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 37. Asia-Pacific Immunotherapy Drugs for Multiple Myeloma Market Size Growth Rate 2017-2028 (US$ Million)
Figure 38. China Immunotherapy Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 39. Japan Immunotherapy Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 40. South Korea Immunotherapy Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 41. India Immunotherapy Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 42. Australia Immunotherapy Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 43. Taiwan Immunotherapy Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 44. Indonesia Immunotherapy Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 45. Thailand Immunotherapy Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 46. Malaysia Immunotherapy Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 47. Philippines Immunotherapy Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 48. Latin America Immunotherapy Drugs for Multiple Myeloma Market Size Growth Rate 2017-2028 (US$ Million)
Figure 49. Mexico Immunotherapy Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 50. Brazil Immunotherapy Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 51. Argentina Immunotherapy Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 52. Middle East & Africa Immunotherapy Drugs for Multiple Myeloma Market Size Growth Rate 2017-2028 (US$ Million)
Figure 53. Turkey Immunotherapy Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 54. Saudi Arabia Immunotherapy Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 55. U.A.E Immunotherapy Drugs for Multiple Myeloma Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 56. Tonghua Dongbao Pharmaceutical Revenue Growth Rate in Immunotherapy Drugs for Multiple Myeloma Business (2017-2022)
Figure 57. Sumitomo Revenue Growth Rate in Immunotherapy Drugs for Multiple Myeloma Business (2017-2022)
Figure 58. Merck Revenue Growth Rate in Immunotherapy Drugs for Multiple Myeloma Business (2017-2022)
Figure 59. Biogen Revenue Growth Rate in Immunotherapy Drugs for Multiple Myeloma Business (2017-2022)
Figure 60. Schering-Plough Revenue Growth Rate in Immunotherapy Drugs for Multiple Myeloma Business (2017-2022)
Figure 61. Roche Revenue Growth Rate in Immunotherapy Drugs for Multiple Myeloma Business (2017-2022)
Figure 62. Glaxo Revenue Growth Rate in Immunotherapy Drugs for Multiple Myeloma Business (2017-2022)
Figure 63. Chiron Revenue Growth Rate in Immunotherapy Drugs for Multiple Myeloma Business (2017-2022)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Tonghua Dongbao Pharmaceutical Sumitomo Merck Biogen Schering-Plough Roche Glaxo Chiron